SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC50 of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research.
SARS-CoV-2-IN-46 (Compound 8w) (1-10 μm) inhibites SARS-CoV-2 replication above 50% in Calu-3 cells[1].SARS-CoV-2-IN-46 (Compound 8w) (250 μm; 72 h) shows low toxicity in Calu-3 cells[1].
References:
[1]. Caleffi GS, et al. Aurones: A Promising Scaffold to Inhibit SARS-CoV-2 Replication. J Nat Prod. 2023 Jun 23;86(6):1536-1549.
















